Ghrelin is an important orexigenic hormone that reduces fat oxidation and increases adiposity. This study investigated plasma ghrelin levels in Chinese Uygur patients with chronic obstructive pulmonary disease (COPD). Plasma ghrelin and anabolic and catabolic factors were measured in 38 patients and 24 control subjects. COPD patients were divided into two groups based on body mass index (BMI): underweight (BMI < 20 kg/m 2 , n = 18) or normoweight (BMI ≥ 20 kg/m 2 , n = 20). Plasma ghrelin levels were found to be significantly higher in underweight than in normoweight patients or healthy controls. Circulating tumour necrosis factor-a and interleukin-6 concentrations were significantly higher in underweight than in normoweight patients, whereas insulin concentrations were significantly lower. Plasma ghrelin levels correlated negatively with forced expiratory volume in 1 s (FEV 1 ; r = 0.35), but did not significantly correlate with FEV 1 /forced vital capacity. Plasma ghrelin levels were elevated in underweight COPD patients and were associated with cachexia and abnormal pulmonary function.
Introduction
Involuntary weight loss is a common complication of chronic obstructive pulmonary disease (COPD) and has been found to be associated with negative outcomes independent of the degree of airflow limitation. 1 -4 Approximately 50% of hospitalized patients with COPD have been found to be < 90% of their ideal body weight. 5 Moreover, generalized muscle wasting, as well as specific wasting of the diaphragm, has been observed. 6 Low body weight and muscle wasting are associated with accelerated mortality and a decline in clinical status, independent of lung-disease severity. 4, 7, 8 Appropriate therapy that *BW Ying and XB Song contributed equally to this work.
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successfully increases body weight has been found to improve survival rates. 8 Ghrelin, a 28-amino acid peptide secreted mainly from the stomach, was isolated in 1999 as the endogenous ligand for the growth hormone secretagogue receptor (GHS-R). 9, 10 Ghrelin is thought to be an important orexigenic hormone 11 that reduces fat oxidation and increases adiposity. 12 Plasma ghrelin levels are inversely related to body mass index (BMI): levels increase with weight loss induced by caloric restriction. 13, 14 Multiple inflammatory cytokines, including interleukin (IL)-6, IL-1β and tumour necrosis factor-α (TNF-α), are also though to contribute to the development of weight loss; however, ghrelin administration can antagonize the effect of cytokines on appetite and body weight. 15 The Uygurs are one of China's minority ethnic groups and COPD is currently the leading cause of death in this population. 16 Although elevated plasma ghrelin levels have been reported in underweight patients with COPD, 17 little information is available regarding the pathophysiology of ghrelin in Chinese Uygur COPD patients. Genetic factors are important in the progression of COPD and it is likely that different populations have different COPD pathophysiological characteristics. For these reasons it was decided to carry out the current investigation into whether plasma ghrelin levels are elevated in Chinese Uygur patients with COPD.
Patients and methods

PATIENTS
Chinese Uygur patients with COPD, diagnosed according to the Global Initiative for Chronic Obstructive Lung Disease criteria, 18 were included in the study. They were divided into two groups based on BMI: underweight (BMI < 20 kg/m 2 ) or normoweight (BMI ≥ 20 kg/m 2 ). All patients were required to be clinically stable at the time of evaluation. The study also included Chinese Uygur control subjects with normal pulmonary function.
The study protocol was approved by the Institutional Review Board of West China Hospital, Sichuan University, and all participants provided written informed consent.
PULMONARY FUNCTION TEST
Pulmonary function was tested by measurement of forced expiratory volume in 1 s (FEV 1 ) and forced vital capacity (FVC) using a pulmonary function test (CHESTAC-33-8800, Chest Ltd, Tokyo, Japan), conducted according to the American Thoracic Society's performance requirements. 19 The FEV 1 /FVC ratio was calculated.
BLOOD SAMPLES AND LABORATORY ANALYSES
Plasma samples were collected the morning after an overnight fast into ethylenediaminetetraacetic acid-containing tubes.
Plasma was separated by centrifugation at 1200 g (2600 rpm) for 15 min at 4 ºC (model M180572 centrifuge; Beckman Coulter. Fullerton, CA, USA). After centrifugation, plasma samples were stored at -20 ºC until use.
Plasma ghrelin levels were measured by radioimmunoassay as described previously. 20 Plasma IL-6, TNF-α and insulin concentrations were measured using human enzyme-linked immunosorbent assays (ELISA; Quantikine ® HS ELISA, R&D Systems Europe, Abingdon, UK). Transferrin levels were measured by nephelometry. ). There were no significant differences in terms of smoking history between underweight and normoweight COPD patients. The mean smoking history was significantly higher in patients with COPD compared with control subjects.
STATISTICAL ANALYSIS
PLASMA CATABOLIC AND ANABOLIC FACTORS
Levels of the catabolic factors TNF-α and IL-6 were significantly higher in both COPD groups compared with control subjects, and were significantly higher in underweight COPD patients compared with normoweight COPD patients (P < 0.01; Table 1 ). In contrast, levels of the anabolic factor, insulin, were significantly lower in both COPD groups than in control subjects, and were also significantly lower in underweight compared with normoweight COPD patients (P < 0.01; Table 1 ).
Plasma triglyceride and transferrin levels were significantly lower in all COPD patients than in control subjects and were 
PLASMA GHRELIN LEVELS
Plasma levels of ghrelin were significantly higher in patients with COPD than in control subjects (254.03 ± 101.83 versus 166.31 ± 37.89 fmol/ml; P < 0.001). Additionally, plasma ghrelin levels were significantly higher in underweight COPD patients (312.69 ± 106.40 fmol/ml) compared with both normoweight patients and control subjects (201.23 ± 62.19 and 166.31 ± 37.89 fmol/ml, respectively) (Fig. 1) .
In the total population plasma ghrelin levels correlated negatively with BMI (r = -0.35; P < 0.05) and with plasma insulin levels (r = -0.84, P < 0.01), and correlated positively with plasma TNF-α levels (r = 0.85, P < 0.01) (Fig. 2) . Plasma ghrelin levels correlated negatively with FEV 1 (r = -0.35, P < 0.05), but were not significantly correlated with FEV 1 /FVC (r = -0.20, P > 0.05) (Fig. 3) .
Discussion
The present study investigated plasma ghrelin levels in Chinese Uygurs with COPD. The Uygurs are one of China's minority ethnic groups and COPD is currently the leading cause of death. 16 Elevated plasma ghrelin levels have been reported in underweight patients with COPD, 17 however little data are available on the pathophysiology of ghrelin in Chinese Uygur COPD patients. The present study demonstrated that plasma ghrelin levels are elevated in Chinese Uygur COPD patients and that plasma ghrelin levels were higher in underweight patients than in normoweight patients and control subjects. Moreover, plasma ghrelin levels correlated negatively with BMI and plasma insulin levels, and correlated positively with plasma TNF-α levels in Chinese Uygur patients with COPD. Plasma ghrelin levels also correlated with FEV 1 .
Ghrelin is the natural ligand for the GHS-R, which is present on pituitary cells that Under-weight COPD Plasma ghrelin in Chinese Uygur COPD patients FIGURE 2: Relationship in the total population between plasma ghrelin levels and (A) body mass index in underweight and normoweight patients with chronic obstructive pulmonary disease (COPD), and between (B) plasma ghrelin and tumour necrosis factor-α (TNF-α) levels and (C) plasma ghrelin and plasma insulin levels Plasma insulin (µU/ml) 6.00 7.00 8.00 9.00 secrete growth hormone. 10 Ghrelin has profound somatotrophic, adipogenic, and orexigenic properties that increase body weight and food intake, thus ghrelin is implicated in a variety of altered-energy states such as obesity, eating disorders, neoplasia, and cachexia. 12, 21, 22 Although many studies have focused on the role of ghrelin in cancer anorexia, there is little research on its role in pulmonary cachexia. 23 -25 In the present study, plasma triglyceride and transferrin levels were lower in underweight COPD patients than in normoweight patients, suggesting that the underweight patients were malnourished. Additionally, plasma ghrelin levels were higher in underweight patients than normoweight patients, and a negative relationship was demonstrated between plasma ghrelin levels and BMI which shows that, in a pulmonary cachectic state, plasma ghrelin levels are increased. Previous research has demonstrated that the development of cachexia in COPD patients is associated with hormonal changes and cytokine activation. 25 In the current study, levels of the anabolic factor, insulin, were significantly lower in underweight COPD patients than in normoweight patients, whereas levels of the catabolic factors TNF-α and IL-6 were significantly higher in underweight patients than in normoweight patients. In addition, plasma ghrelin levels were positively correlated with plasma TNF-α levels and negatively correlated with plasma insulin levels. These results raise the possibility that an increase in plasma ghrelin levels may represent a compensatory BW Ying, XB Song, H Fan et al. Plasma ghrelin in Chinese Uygur COPD patients mechanism under conditions of anabolic-catabolic imbalance in cachectic patients with COPD.
The present study also showed a significant negative correlation between plasma ghrelin levels and FEV 1 , but not with FEV 1 /FVC. Thus, elevated ghrelin levels may be associated with abnormal pulmonary function in COPD patients. Since GHS-R (which is a receptor for ghrelin) is expressed in the lungs, 26 further studies are warranted to investigate the role of ghrelin in this area.
Several studies have examined the effects of medical treatment on pulmonary cachexia and found that some interventions are associated with adverse reactions. 27 Since ghrelin is a novel endogenous growth hormone-releasing peptide that may affect energy metabolism, it may be interesting to investigate further whether treatment with ghrelin would attenuate the development of cachexia in COPD patients.
In conclusion, plasma ghrelin levels were increased in underweight Chinese Uygur patients with COPD and seemed to be related to a cachectic state and pulmonary dysfunction.
